Creating a new generation of small molecule protease inhibitors

Investors Overview

Corporate Profile

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs.

NASDAQ | KALV (Common Stock)
$8.48-0.16 (1.85%)
Stock chart for: KALV.O.  Currently trading at $8.48 with a 52 week high of $15.80 and a 52 week low of $5.48.
Data provided by Nasdaq. Minimum 15 minutes delayed.
View Attributions and Sources

Featured Presentations

Download Documentation Corporate Presentation